Intravenous iron sucrose: establishing a safe dose.

Area of Science:

• Nephrology
• Pharmacology
• Hematology

Background:

• Epoetin therapy often necessitates intravenous (IV) iron supplementation for optimal efficacy.
• Iron sucrose is an effective and safe IV iron preparation, but optimal dosing guidelines are lacking.
• Patients with renal failure frequently require iron supplementation to manage anemia.

Purpose of the Study:

• To prospectively investigate various intravenous iron sucrose dosing regimens in patients with renal failure.
• To establish safe and effective treatment strategies for intravenous iron sucrose administration.

Main Methods:

• A prospective study involving 249 patients and 335 intravenous iron sucrose infusions over four phases.
• Doses tested included 200 mg (n=89), 500 mg (n=22), 300 mg (n=189), and 400 mg (n=35), all infused over 2 hours.
• Adverse events were monitored and recorded for each dosing regimen.

Main Results:

• The 200 mg and 300 mg doses administered over 2 hours showed no adverse events.
• The 500 mg dose resulted in adverse reactions (dizziness, hypotension, nausea) in 8 of 22 patients.
• The 400 mg dose led to adverse events (hypotension, nausea, lower back pain) in 2 of 35 patients.

Conclusions:

• Intravenous iron sucrose doses of 200 mg and 300 mg infused over 2 hours are safe for renal failure patients.
• Higher doses (400 mg and 500 mg) administered over 2 hours exhibit an unacceptably high incidence of adverse events.
• Consideration should be given to administering higher iron sucrose doses over extended periods to mitigate risks.